Pentwater Capital Management LP acquired a new position in shares of Medidata Solutions Inc (NASDAQ:MDSO) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 274,700 shares of the company’s stock, valued at approximately $24,863,000.
A number of other hedge funds also recently bought and sold shares of the business. Marshall Wace LLP lifted its stake in Medidata Solutions by 511.0% in the second quarter. Marshall Wace LLP now owns 52,654 shares of the company’s stock valued at $4,765,000 after buying an additional 44,036 shares during the last quarter. Nomura Holdings Inc. bought a new stake in Medidata Solutions in the second quarter valued at $2,500,000. Morgan Stanley lifted its stake in Medidata Solutions by 449.5% in the second quarter. Morgan Stanley now owns 457,826 shares of the company’s stock valued at $41,437,000 after buying an additional 374,509 shares during the last quarter. AQR Capital Management LLC lifted its stake in Medidata Solutions by 403.2% in the second quarter. AQR Capital Management LLC now owns 24,400 shares of the company’s stock valued at $2,208,000 after buying an additional 19,551 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Medidata Solutions in the second quarter valued at $14,784,000. Institutional investors own 91.31% of the company’s stock.
A number of equities research analysts have issued reports on MDSO shares. Piper Jaffray Companies cut Medidata Solutions from an “overweight” rating to a “neutral” rating in a research note on Wednesday, June 12th. BidaskClub lowered Medidata Solutions from a “hold” rating to a “sell” rating in a report on Saturday, September 14th. William Blair lowered Medidata Solutions from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 12th. Wells Fargo & Co reissued a “hold” rating on shares of Medidata Solutions in a report on Thursday, June 13th. Finally, JPMorgan Chase & Co. raised Medidata Solutions from an “underweight” rating to a “neutral” rating in a report on Wednesday, June 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. Medidata Solutions currently has an average rating of “Hold” and an average price target of $84.27.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Monday, July 22nd. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.31. The company had revenue of $180.50 million for the quarter, compared to analyst estimates of $179.95 million. Medidata Solutions had a return on equity of 8.64% and a net margin of 6.43%. The company’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period last year, the company earned $0.43 earnings per share. On average, equities research analysts expect that Medidata Solutions Inc will post 0.78 EPS for the current year.
Medidata Solutions Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Article: How do CD ladders protect against rising interest rates?
Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.